A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2016
Price : $35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 29 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Feb 2015 Planned End Date changed from 1 Dec 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
- 05 Feb 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov record.